EML4 and adenocarcinoma: Further analysis indicated in the 32 cases of non-smoking, female, adenocarcinoma patients that the frequency of EGFR exon mutations and EML4-ALK translocation were 62.5%% (20/32) and 15.63% (5/32), respectively, which covers all 78.13% (25/32) of these patients.